| Mahendra Narendran, | |
|
138 Sherlock Dr, Statesville, NC 28625-1916 | |
| (704) 873-1021 | |
| (704) 838-0706 |
| Full Name | Mahendra Narendran |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 22 Years |
| Location | 138 Sherlock Dr, Statesville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316074693 | NPI | - | NPPES |
| 5919461 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 2011-01784 (North Carolina) | Secondary |
| 207R00000X | Internal Medicine | 2011-01784 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gentiva Health Services | Hickory, NC | Home health agency |
| Iredell Home Health | Statesville, NC | Home health agency |
| Bayada Home Health Care, Inc | Salisbury, NC | Home health agency |
| Iredell Memorial Hospital Inc | Statesville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Healthcare Pa | 9638070683 | 222 |
News Archive
Advanced Cell Technology, Inc. announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company's plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
For disabling hand contractures caused by Dupuytren's disease, patients prefer a percutaneous needle fasciotomy procedure despite the higher contracture recurrence rate when compared to conventional surgery.
Computer Sciences Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved its Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin, to treat rare adverse reactions to smallpox vaccination.
Many cancers can be successfully treated, but treatment itself often comes with risks as well. Cancer therapy that uses anthracyclines-a class of commonly used chemotherapy drugs-has been associated with heart damage that can eventually result in heart failure. It is thought to be the reason why heart disease is a leading cause of death in cancer survivors, immediately following cancer recurrence.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
› Verified 3 days ago
| Entity Name | Piedmont Healthcare Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912999897 PECOS PAC ID: 9638070683 Enrollment ID: O20040114000339 |
News Archive
Advanced Cell Technology, Inc. announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company's plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
For disabling hand contractures caused by Dupuytren's disease, patients prefer a percutaneous needle fasciotomy procedure despite the higher contracture recurrence rate when compared to conventional surgery.
Computer Sciences Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved its Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin, to treat rare adverse reactions to smallpox vaccination.
Many cancers can be successfully treated, but treatment itself often comes with risks as well. Cancer therapy that uses anthracyclines-a class of commonly used chemotherapy drugs-has been associated with heart damage that can eventually result in heart failure. It is thought to be the reason why heart disease is a leading cause of death in cancer survivors, immediately following cancer recurrence.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mahendra Narendran, Po Box 1845, Statesville, NC 28687-1845 Ph: (704) 873-1021 | Mahendra Narendran, 138 Sherlock Dr, Statesville, NC 28625-1916 Ph: (704) 873-1021 |
News Archive
Advanced Cell Technology, Inc. announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company's plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
For disabling hand contractures caused by Dupuytren's disease, patients prefer a percutaneous needle fasciotomy procedure despite the higher contracture recurrence rate when compared to conventional surgery.
Computer Sciences Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved its Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin, to treat rare adverse reactions to smallpox vaccination.
Many cancers can be successfully treated, but treatment itself often comes with risks as well. Cancer therapy that uses anthracyclines-a class of commonly used chemotherapy drugs-has been associated with heart damage that can eventually result in heart failure. It is thought to be the reason why heart disease is a leading cause of death in cancer survivors, immediately following cancer recurrence.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
› Verified 3 days ago
Ms. Virginia Fredericka Wright, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1022 Shelton Ave, Statesville, NC 28677 Phone: 704-838-1234 Fax: 704-768-2081 | |
Jose Eduardo Perez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 208 Old Mocksville Rd, Statesville, NC 28625 Phone: 704-838-8240 Fax: 704-384-5360 | |
Dr. Nasib Ayoubi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 770 Hartness Rd, Statesville, NC 28677 Phone: 704-872-6810 | |
Elias David Ruiz Valdez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 557 Brookdale Dr, Statesville, NC 28677 Phone: 704-873-5661 | |
Neil M Kassman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 208 Old Mocksville Rd, Statesville, NC 28625 Phone: 704-838-8215 | |
Dr. Robert Adjamah Aryeetey, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 276 Old Mocksville Road, Suite 1100, Statesville, NC 28625 Phone: 704-878-2523 Fax: 704-878-6417 | |
Dr. James Hedrick Bradford, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 738 Bryant St, Suite A, Statesville, NC 28677 Phone: 704-873-1180 Fax: 704-873-1116 |